1. Home
  2. RPD vs COLL Comparison

RPD vs COLL Comparison

Compare RPD & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rapid7 Inc.

RPD

Rapid7 Inc.

N/A

Current Price

$14.44

Market Cap

746.5M

Sector

Technology

ML Signal

N/A

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

N/A

Current Price

$24.78

Market Cap

768.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RPD
COLL
Founded
2000
2002
Country
United States
United States
Employees
N/A
423
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
746.5M
768.2M
IPO Year
2015
2015

Fundamental Metrics

Financial Performance
Metric
RPD
COLL
Price
$14.44
$24.78
Analyst Decision
Hold
Buy
Analyst Count
24
8
Target Price
$15.50
★ $44.00
AVG Volume (30 Days)
★ 1.9M
533.8K
Earning Date
11-04-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
0.16
★ 0.64
Revenue
$685,083,000.00
★ $780,567,000.00
Revenue This Year
N/A
$6.59
Revenue Next Year
N/A
$1.89
P/E Ratio
$95.75
★ $39.44
Revenue Growth
N/A
N/A
52 Week Low
$4.97
$21.43
52 Week High
$18.56
$50.79

Technical Indicators

Market Signals
Indicator
RPD
COLL
Relative Strength Index (RSI) 49.55 53.68
Support Level $11.04 $21.67
Resistance Level $18.56 $26.39
Average True Range (ATR) 1.25 0.92
MACD -0.14 0.05
Stochastic Oscillator 25.25 44.20

Price Performance

Historical Comparison
RPD
COLL

About RPD Rapid7 Inc.

Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.

Share on Social Networks: